| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Allison J. Cowin | Q38800671 |
| Natalie E Stevens | Q56872628 | ||
| Zlatko Kopecki | Q61155102 | ||
| P2860 | cites work | Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. | Q50910869 |
| Pivotal Role of Lesional and Perilesional T/B Lymphocytes in Pemphigus Pathogenesis. | Q50925874 | ||
| CD4+CD25high regulatory T cells are markedly decreased in blood of patients with pemphigus vulgaris. | Q51041309 | ||
| A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid. | Q51051272 | ||
| Rituximab Treatment for Recalcitrant Dermatitis Herpetiformis. | Q51230713 | ||
| Topically Applied Hsp90 Blocker 17AAG Inhibits Autoantibody-Mediated Blister-Inducing Cutaneous Inflammation. | Q51472998 | ||
| Autoantibody Profile Differentiates between Inflammatory and Noninflammatory Bullous Pemphigoid. | Q51636888 | ||
| Specific Inhibition of Complement Activation Significantly Ameliorates Autoimmune Blistering Disease in Mice. | Q52332743 | ||
| Pemphigus foliaceus IgG causes dissociation of desmoglein 1-containing junctions without blocking desmoglein 1 transinteraction | Q24530223 | ||
| Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. | Q24537348 | ||
| Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice | Q24564582 | ||
| Novel human alpha9 acetylcholine receptor regulating keratinocyte adhesion is targeted by Pemphigus vulgaris autoimmunity | Q24669539 | ||
| Cytoskeletal Regulation of Inflammation and Its Impact on Skin Blistering Disease Epidermolysis Bullosa Acquisita | Q26740099 | ||
| The Role of Damage-Associated Molecular Patterns in Human Diseases: Part I - Promoting inflammation and immunity | Q26864215 | ||
| Black patients of African descent and HLA-DRB1*15:03 frequency overrepresented in epidermolysis bullosa acquisita | Q84742960 | ||
| Up-regulation of CCL11 and CCL26 is associated with activated eosinophils in bullous pemphigoid | Q85068810 | ||
| Risk factors for bullous pemphigoid in the elderly: a prospective case-control study | Q85190909 | ||
| British Association of Dermatologists' guidelines for the management of bullous pemphigoid 2012 | Q85344681 | ||
| Topically applied flightless I neutralizing antibodies improve healing of blistered skin in a murine model of epidermolysis bullosa acquisita | Q85637843 | ||
| Localized bullous pemphigoid occurring on surgical scars | Q86940956 | ||
| Regulatory T-cell deficiency leads to pathogenic bullous pemphigoid antigen 230 autoantibody and autoimmune bullous disease | Q88500454 | ||
| The Role of Eosinophils in Bullous Pemphigoid: A Developing Model of Eosinophil Pathogenicity in Mucocutaneous Disease | Q90455736 | ||
| Case of autoimmune intraepidermal and subepidermal blistering disease in which autoantibodies to desmoglein 1 and BP230 coexist | Q90483080 | ||
| Therapeutic Effect of a Novel Phosphatidylinositol-3-Kinase δ Inhibitor in Experimental Epidermolysis Bullosa Acquisita | Q90534624 | ||
| Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients | Q90846954 | ||
| Dermatitis Herpetiformis and Celiac Disease Increase the Risk of Bullous Pemphigoid | Q90909224 | ||
| IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid | Q91465395 | ||
| Drug Discovery for Pemphigoid Diseases | Q91750461 | ||
| Paraneoplastic pemphigus: a short review | Q28077638 | ||
| Autoimmunity against desmosomal cadherins in pemphigus | Q28137910 | ||
| The diagnosis and treatment of dermatitis herpetiformis | Q28262298 | ||
| A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS) | Q28661698 | ||
| Eosinophils in Autoimmune Diseases. | Q33607031 | ||
| Autoimmune blistering diseases in females: a review | Q33640302 | ||
| Mechanisms of Autoantibody-Induced Pathology. | Q33740580 | ||
| Correlation between IL36α and IL17 and Activity of the Disease in Selected Autoimmune Blistering Diseases | Q33762424 | ||
| Frequency of Neurological Disorders in Bullous Pemphigoid Patients: A Cross-Sectional Study | Q33775465 | ||
| Epitope spreading: protection from pathogens, but propagation of autoimmunity? | Q34328092 | ||
| Dermatitis herpetiformis: pathophysiology, clinical presentation, diagnosis and treatment | Q34504412 | ||
| Persistent autoantibody-production by intermediates between short-and long-lived plasma cells in inflamed lymph nodes of experimental epidermolysis bullosa acquisita | Q35080528 | ||
| Epidermolysis bullosa: directions for future research and new challenges for treatment | Q35099773 | ||
| Nanorobotic investigation identifies novel visual, structural and functional correlates of autoimmune pathology in a blistering skin disease model. | Q35242526 | ||
| Environmental risk factors in endemic pemphigus foliaceus (fogo selvagem). | Q35660724 | ||
| Identification of a Functional Risk Variant for Pemphigus Vulgaris in the ST18 Gene | Q36009248 | ||
| Critical Role of the Neonatal Fc Receptor (FcRn) in the Pathogenic Action of Antimitochondrial Autoantibodies Synergizing with Anti-desmoglein Autoantibodies in Pemphigus Vulgaris | Q36093026 | ||
| Three case reports of post immunization and post viral Bullous Pemphigoid: looking for the right trigger | Q36287750 | ||
| Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice | Q36399066 | ||
| Cell damage and autoimmunity: a critical appraisal | Q36440448 | ||
| Autoantibodies in the autoimmune disease pemphigus foliaceus induce blistering via p38 mitogen-activated protein kinase-dependent signaling in the skin | Q37061072 | ||
| T cell-independent B cell activation induces immunosuppressive sialylated IgG antibodies. | Q37123859 | ||
| Autoantibodies other than Anti-desmogleins in Pemphigus Vulgaris Patients | Q37618577 | ||
| Th1/Th17-Related Cytokines and Chemokines and Their Implications in the Pathogenesis of Pemphigus Vulgaris. | Q37685685 | ||
| Long-lived autoreactive plasma cells drive persistent autoimmune inflammation | Q37833902 | ||
| Pemphigus autoimmunity: hypotheses and realities | Q37937040 | ||
| Current therapy of the pemphigus group | Q37964163 | ||
| Where does rituximab fit in the treatment of autoimmune mucocutaneous blistering skin disease? | Q38004882 | ||
| Relationship between radiation therapy and bullous pemphigoid | Q38214803 | ||
| Malignancies in bullous pemphigoid: A controversial association | Q38598962 | ||
| Immune mechanism-targeted treatment of experimental epidermolysis bullosa acquisita. | Q38608315 | ||
| Dramatic resolution of bullous pemphigoid after surgery for gastric cancer: A case report | Q38669806 | ||
| Epidermolysis Bullosa Acquisita: From Pathophysiology to Novel Therapeutic Options. | Q38695599 | ||
| Three Cases of Bullous Pemphigoid Associated with Dipeptidyl Peptidase-4 Inhibitors - One due to Linagliptin. | Q38714800 | ||
| Increasing the Complement of Therapeutic Options in Bullous Pemphigoid | Q48516802 | ||
| British Association of Dermatologists' guidelines for the management of pemphigus vulgaris 2017. | Q49382688 | ||
| Association between HLA-DQB1 polymorphisms and pemphigus vulgaris: A meta-analysis. | Q49576144 | ||
| HLA-DQB1*03:01 as a Biomarker for Genetic Susceptibility to Bullous Pemphigoid Induced by DPP-4 Inhibitors. | Q50083924 | ||
| Whole-Genome Expression Profiling in Skin Reveals SYK As a Key Regulator of Inflammation in Experimental Epidermolysis Bullosa Acquisita. | Q50333828 | ||
| High risk of death in elderly patients with extensive bullous pemphigoid. | Q50894682 | ||
| Update on the role of plasmacytoid dendritic cells in inflammatory/autoimmune skin diseases | Q38720050 | ||
| Discovering potential drug-targets for personalized treatment of autoimmune disorders - what we learn from epidermolysis bullosa acquisita. | Q38720806 | ||
| Mechanisms of Disease: Pemphigus and Bullous Pemphigoid. | Q38747187 | ||
| Signalling and targeted therapy of inflammatory cells in epidermolysis bullosa acquisita. | Q38749755 | ||
| Plasma cells as an innovative target in autoimmune disease with renal manifestations | Q38753491 | ||
| Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis | Q38852573 | ||
| First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial | Q38876705 | ||
| Clinical features and diagnosis of epidermolysis bullosa acquisita | Q38942490 | ||
| Bullous pemphigoid autoantibodies directly induce blister formation without complement activation | Q38952869 | ||
| Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations. | Q39084627 | ||
| IL-17 and IL-22 in immunity: Driving protection and pathology | Q39179415 | ||
| Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP). | Q39952624 | ||
| Autoantibodies to type VII collagen mediate Fcgamma-dependent neutrophil activation and induce dermal-epidermal separation in cryosections of human skin | Q40719797 | ||
| Development of chimeric molecules for recognition and targeting of antigen-specific B cells in pemphigus vulgaris | Q40772545 | ||
| Analysis of Serum Cytokine Profile in Pemphigus | Q40955447 | ||
| Pemphigus vulgaris-IgG causes a rapid depletion of desmoglein 3 (Dsg3) from the Triton X-100 soluble pools, leading to the formation of Dsg3-depleted desmosomes in a human squamous carcinoma cell line, DJM-1 cells | Q40981530 | ||
| Caspase-1-independent IL-1 release mediates blister formation in autoantibody-induced tissue injury through modulation of endothelial adhesion molecules | Q41184705 | ||
| Neurological disorders in patients with bullous pemphigoid: clinical and experimental investigations | Q41479818 | ||
| Transforming growth factor-beta up-regulates type VII collagen gene expression in normal and transformed epidermal keratinocytes in culture | Q41660060 | ||
| Regulatory T cells as well as IL-10 are reduced in the skin of patients with dermatitis herpetiformis. | Q41736822 | ||
| A possible role for CD8+ T lymphocytes in the cell-mediated pathogenesis of pemphigus vulgaris | Q41952852 | ||
| Association of bullous pemphigoid with malignancy: a myth or reality? | Q42073366 | ||
| Cutting Edge: Brazilian pemphigus foliaceus anti-desmoglein 1 autoantibodies cross-react with sand fly salivary LJM11 antigen | Q42261879 | ||
| Reduced skin blistering in experimental epidermolysis bullosa acquisita after anti-TNF treatment | Q42320550 | ||
| T cells mediate autoantibody-induced cutaneous inflammation and blistering in epidermolysis bullosa acquisita | Q42358830 | ||
| Refractory pemphigus foliaceus associated with herpesvirus infection: case report | Q42369499 | ||
| The immune response to secondary necrotic cells. | Q42371859 | ||
| A case of paraneoplastic bullous pemphigoid in association with squamous cell carcinoma of lung | Q42423746 | ||
| Transforming growth factor-beta promotes deposition of collagen VII in a modified organotypic skin model. | Q42499160 | ||
| The pathophysiology of autoimmune blistering diseases | Q42710748 | ||
| Induction of epidermolysis bullosa acquisita in mice by passive transfer of autoantibodies from patients | Q43905705 | ||
| Development of pemphigus herpetiformis in a patient with psoriasis receiving UV-light treatment | Q44789646 | ||
| GM-CSF modulates autoantibody production and skin blistering in experimental epidermolysis bullosa acquisita | Q44811602 | ||
| Two distinct viral infections complicating pemphigus foliaceus. | Q45096604 | ||
| B cells, dendritic cells, and macrophages are required to induce an autoreactive CD4 helper T cell response in experimental epidermolysis bullosa acquisita | Q45397909 | ||
| Regulatory T Cells Suppress Inflammation and Blistering in Pemphigoid Diseases | Q46244253 | ||
| Calcitriol Treatment Ameliorates Inflammation and Blistering in Mouse Models of Epidermolysis Bullosa Acquisita. | Q46301824 | ||
| The Anti-C1s Antibody TNT003 Prevents Complement Activation in the Skin Induced by Bullous Pemphigoid Autoantibodies. | Q46401885 | ||
| Evidence for a role of eosinophils in blister formation in bullous pemphigoid | Q46425853 | ||
| Langerhans Cells Prevent Autoimmunity via Expansion of Keratinocyte Antigen-Specific Regulatory T Cells. | Q47200811 | ||
| Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy. | Q47277879 | ||
| Eosinophils mediate tissue injury in autoimmune skin disease bullous pemphigoid | Q47287873 | ||
| Association of HLA class I and class II alleles with bullous pemphigoid in Chinese Hans | Q47297269 | ||
| Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris | Q47643831 | ||
| Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management | Q47988514 | ||
| Dermatitis herpetiformis: a cutaneous manifestation of coeliac disease | Q48028538 | ||
| The Role of Mast Cells in Autoimmune Bullous Dermatoses. | Q52655233 | ||
| T cell participation in autoreactivity to NC16a epitopes in bullous pemphigoid. | Q52996461 | ||
| Association of Bullous Pemphigoid and Malignant Neoplasms. | Q53620287 | ||
| Bullous pemphigoid associated with chronic hepatitis C virus infection in a hepatitis B virus endemic area: A case report. | Q54092393 | ||
| Increased Serum Levels of Th2-type Cytokines and Eotaxin in Fibrillar-type Dermatitis Herpetiformis. | Q54148911 | ||
| B Cell Modulation Strategies in Autoimmune Diseases: New Concepts. | Q54980047 | ||
| The Autoimmune Skin Disease Bullous Pemphigoid: The Role of Mast Cells in Autoantibody-Induced Tissue Injury. | Q55104920 | ||
| Autoantibody Signaling in Pemphigus Vulgaris: Development of an Integrated Model. | Q55110690 | ||
| Humoral Epitope Spreading in Autoimmune Bullous Diseases. | Q55262188 | ||
| Non-Desmoglein Antibodies in Patients With Pemphigus Vulgaris. | Q55375191 | ||
| Autoimmune Diseases and Their Manifestations on Oral Cavity: Diagnosis and Clinical Management. | Q55413268 | ||
| Emerging treatment options for the management of pemphigus vulgaris. | Q55433740 | ||
| Regulatory T-cell deficiency and autoimmune skin disease: Beyond the scurfy mouse and immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome | Q56963556 | ||
| Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the | Q57490881 | ||
| Identification of Quantitative Trait Loci in Experimental Epidermolysis Bullosa Acquisita | Q57836499 | ||
| The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations | Q58735688 | ||
| Comorbidities and Treatment Strategies in Bullous Pemphigoid: An Appraisal of the Existing Litterature | Q58764804 | ||
| The Genetics of Pemphigus Vulgaris | Q58781495 | ||
| Diagnosis of Autoimmune Blistering Diseases | Q59132166 | ||
| Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific Conference | Q59341201 | ||
| Complement-Activating Capacity of Autoantibodies Correlates With Disease Activity in Bullous Pemphigoid Patients | Q59791456 | ||
| Demonstration of Epitope-Spreading Phenomena in Bullous Pemphigoid: Results of a Prospective Multicenter Study | Q60240341 | ||
| Epidermolysis Bullosa Acquisita: The 2019 Update | Q61449510 | ||
| The Diagnosis and Blistering Mechanisms of Mucous Membrane Pemphigoid | Q61810264 | ||
| Bullous pemphigoid associated with radiotherapy for esophageal carcinoma | Q70175807 | ||
| Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease | Q70227278 | ||
| Distribution of HLA class II alleles in Korean patients with epidermolysis bullosa acquisita | Q71970770 | ||
| Immune modulation in pemphigus vulgaris: role of CD28 and IL-10 | Q73289709 | ||
| Inflammatory variant of epidermolysis bullosa acquisita with IgG autoantibodies against type VII collagen and laminin alpha3 | Q73454179 | ||
| Suction blister model of wound healing | Q73571221 | ||
| Epitope spreading in paraneoplastic pemphigus: autoimmune induction in antibody-mediated blistering skin diseases | Q73803284 | ||
| Electron microscopy and morphometry enhances differentiation of epidermolysis bullosa subtypes. With normal values for 24 parameters in skin | Q74096946 | ||
| The anti-desmoglein 1 autoantibodies in pemphigus vulgaris sera are pathogenic | Q77419396 | ||
| Increased expression of Th2-associated chemokines in bullous pemphigoid disease. Role of eosinophils in the production and release of these chemokines | Q79747218 | ||
| The alternative pathway of complement activation is critical for blister induction in experimental epidermolysis bullosa acquisita | Q80257413 | ||
| Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept | Q81026380 | ||
| Immunological mechanisms and clinical implications of regulatory T cell deficiency in a systemic autoimmune disorder: roles of IL-2 versus IL-15 | Q81239549 | ||
| Radiation therapy as a trigger factor for initially localized bullous pemphigoid | Q81502830 | ||
| IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment | Q83258289 | ||
| Heat-shock protein 90 inhibition in autoimmunity to type VII collagen: evidence that nonmalignant plasma cells are not therapeutic targets | Q83853686 | ||
| Antigen-independent development of Foxp3+ regulatory T cells suppressing autoantibody production in experimental pemphigus vulgaris | Q83984319 | ||
| Autoimmune diseases of the skin | Q84072261 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P921 | main subject | skin | Q1074 |
| autoimmunity | Q192360 | ||
| epidermis | Q212743 | ||
| blister | Q276469 | ||
| P304 | page(s) | 1089 | |
| P577 | publication date | 2019-05-14 | |
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | Skin Barrier and Autoimmunity-Mechanisms and Novel Therapeutic Approaches for Autoimmune Blistering Diseases of the Skin | |
| P478 | volume | 10 |
Search more.